Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FASTIMMUNE: Diet + Atezolizumab in SCLC
NCT05703997Phase 2Not yet recruiting
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Jan 2023
- Primary completion
- Jan 2025
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in small cell lung cancer (SCLC), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Progression-Free Survival rate at 6 months. Planned start Jan 2023; status: not yet recruiting.
02
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05703997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05703997.